We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

21 hedge funds and large institutions have $9.64M invested in Evoke Pharma in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

22% more capital invested

Capital invested by funds: $7.92M → $9.64M (+$1.72M)

5% more funds holding

Funds holding: 20 → 21 (+1)

0.25% more ownership

Funds ownership: 18.89% → 19.14% (+0.25%)

Holders
21
Holders Change
+1
Holders Change %
+5%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BFM
Boothbay Fund Management
New York
+$112K
2
JP Morgan Chase
JP Morgan Chase
New York
+$103K
3
Morgan Stanley
Morgan Stanley
New York
+$31.1K
4
VF
Virtu Financial
New York
+$30.3K
5
UBS Group
UBS Group
Switzerland
+$18K

Top Sellers

Rank Fund Capital Flow
1
Bank of New York Mellon
Bank of New York Mellon
New York
-$62K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$32K
3
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$24.7K
4
TSS
Two Sigma Securities
New York
-$798

EVOK Hedge Fund Activity: Q3 2018 in Review

21 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q3 2018, worth a combined $9.64M — up 22% from $7.92M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new EVOK positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $112K. The largest seller was Bank of New York Mellon, exiting entirely with an estimated $62K sold.

  • 21 institutional investors held Evoke Pharma (EVOK) as of Q3 2018, up from 20 in Q2 2018.
  • Funds reported $9.64M of Evoke Pharma stock for Q3 2018, up 22% quarter-over-quarter.
  • 3 funds opened new Evoke Pharma positions in Q3 2018 and 2 closed out, a net change of +1 holder.
  • The largest Evoke Pharma buyer in Q3 2018 was Boothbay Fund Management, an estimated $112K added.
  • The largest Evoke Pharma seller in Q3 2018 was Bank of New York Mellon, an estimated $62K sold.

Based on aggregated 13F filings for Q3 2018.